In this context, the anti‐inflammatory efficacy so far demonstrated in both T2‐high and T2‐low severe asthma and subsequent approval in several countries of the anti‐TSLP monoclonal antibody tezepelumab111 could pave the way for further investigations regarding the putative anti‐tumor immunity‐suppressive role of TSLP in melanoma, as well as the subsequent launch of clinical trials with the ultimate aim to achieve therapeutic approval of this biologic in the dermato‐oncological field. This evidence concerns the gene TSLP and melanoma.